Guzman, Monica L

Publications

Sort by

Co-Author Network

selected publications

Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications. 2023 Academic Article GET IT
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6^th annual ImmunoRad conference. Oncoimmunology. 2023 Review GET IT
Times cited: 511
Understanding the interaction between leukaemia stem cells and their microenvironment to improve therapeutic approaches. British journal of pharmacology. 2023 Review GET IT
Editorial: Measurable residual disease in hematologic malignancies. Frontiers in oncology. 2023 Editorial Article GET IT
Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood advances. 2023 Academic Article GET IT
Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell death & disease. 2023 Academic Article GET IT
Times cited: 2
Global representation among journal editors in haematology: are we diverse, equitable, and inclusive?. The Lancet. Haematology. 2023 Academic Article GET IT
Times cited: 1
The eukaryotic translation initiation factor eIF4E reprograms alternative splicing. The EMBO journal. 2023 Academic Article GET IT
Times cited: 2
Editorial: New immunotherapeutic and pharmacological targets and strategies in haematological malignancies. Frontiers in pharmacology. 2023 Editorial Article GET IT
Times cited: 11
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 Academic Article GET IT
Times cited: 3
Cancer Stem Cells: Biology and Therapeutic Implications. Archives of medical research. 2022 Review GET IT
Times cited: 2
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leukemia research. 2022 Academic Article GET IT
Times cited: 1
Analysis of Plant-Plant Interactions Reveals the Presence of Potent Antileukemic Compounds. Molecules (Basel, Switzerland). 2022 Academic Article GET IT
Times cited: 133
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nature communications. 2022 Academic Article GET IT
Times cited: 12
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nature communications. 2022 Academic Article GET IT
Times cited: 9
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO precision oncology. 2022 Academic Article GET IT
Times cited: 9
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021 Academic Article GET IT
Times cited: 139
Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models. Methods in cell biology. 2021 Academic Article GET IT
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. HemaSphere. 2021 Academic Article GET IT
Times cited: 11
Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL. Frontiers in immunology. 2021 Academic Article GET IT
Times cited: 6
Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 103
Macrophages in Acute Myeloid Leukaemia: Significant Players in Therapy Resistance and Patient Outcomes. Frontiers in cell and developmental biology. 2021 Review GET IT
Times cited: 86
Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. Nature chemical biology. 2021 Academic Article GET IT
Times cited: 18
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ precision oncology. 2021 Academic Article GET IT
Times cited: 224
Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. Blood advances. 2021 Academic Article GET IT
Times cited: 13
BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. Blood. 2021 Academic Article GET IT
Times cited: 12
Clonal hematopoiesis before, during, and after human spaceflight. Cell reports. 2021 Article GET IT
Times cited: 4
Clonal Hematopoiesis Before, During, and After Human Spaceflight. Cell reports. 2020 Academic Article GET IT
Times cited: 15
Synthesis, Crystallography, and Anti-Leukemic Activity of the Amino Adducts of Dehydroleucodine. Molecules (Basel, Switzerland). 2020 Academic Article GET IT
Times cited: 2
Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies. Methods in enzymology. 2020 Academic Article GET IT
Times cited: 8
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. British journal of haematology. 2020 Academic Article GET IT
Times cited: 10
A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond. Cold Spring Harbor perspectives in biology. 2020 Review GET IT
Times cited: 29
Clonal Hematopoiesis and Premalignant Diseases. Cold Spring Harbor perspectives in medicine. 2020 Review GET IT
Times cited: 8
CD123 as a Therapeutic Target Against Malignant Stem Cells. Hematology/oncology clinics of North America. 2020 Review GET IT
Times cited: 16
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 113
The therapeutic landscape for cells engineered with chimeric antigen receptors. Nature biotechnology. 2020 Academic Article GET IT
Times cited: 110
Chaperome Networks - Redundancy and Implications for Cancer Treatment. Advances in experimental medicine and biology. 2020 Review GET IT
Times cited: 10
Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells. Blood advances. 2019 Academic Article GET IT
Times cited: 2
Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer cell. 2019 Academic Article GET IT
Times cited: 29
Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma. Neoplasia (New York, N.Y.). 2019 Academic Article GET IT
Times cited: 9
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer discovery. 2019 Academic Article GET IT
Times cited: 28
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nature nanotechnology. 2019 Academic Article GET IT
Times cited: 169
Approaches to Targeting Cancer Stem Cells in Solid Tumors. Current stem cell research & therapy. 2019 Review GET IT
Times cited: 3
A novel tetrazole analogue of resveratrol is a potent anticancer agent. Bioorganic & medicinal chemistry letters. 2018 Academic Article GET IT
Times cited: 25
Chaperome heterogeneity and its implications for cancer study and treatment. The Journal of biological chemistry. 2018 Review GET IT
Times cited: 32
Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species. Journal of cellular and molecular medicine. 2018 Academic Article GET IT
Times cited: 15
Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. Nature medicine. 2018 Academic Article GET IT
Times cited: 54
Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature medicine. 2018 Academic Article GET IT
Times cited: 338
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica. 2018 Academic Article GET IT
Times cited: 29
Minimal Residual Disease in Acute Myeloid Leukemia. Advances in experimental medicine and biology. 2018 Review GET IT
Times cited: 12
Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents. Anti-cancer agents in medicinal chemistry. 2018 Academic Article GET IT
Times cited: 6
Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment. Oncotarget. 2017 Academic Article GET IT
Times cited: 9
Corrigendum to: "Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers" [EBioMedicine 8 (2016) 117-131]. EBioMedicine. 2017 Academic Article GET IT
Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites. Nature. 2017 Academic Article GET IT
Times cited: 124
Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1. Cell stem cell. 2017 Academic Article GET IT
Times cited: 29
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 11
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 10
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. The Journal of molecular diagnostics : JMD. 2017 Academic Article GET IT
Times cited: 61
GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML. Blood. 2017 Academic Article GET IT
Times cited: 51
Minimal residual disease in acute myelogenous leukemia. International journal of laboratory hematology. 2017 Review GET IT
Times cited: 33
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer discovery. 2017 Academic Article GET IT
Times cited: 84
Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic Progression at the Expense of Normal Lymphopoiesis. Frontiers in immunology. 2017 Academic Article GET IT
Times cited: 9
The epichaperome: the power of many as the power of one. Oncoscience. 2016 Editorial Article GET IT
Times cited: 19
The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016 Academic Article GET IT
Times cited: 167
Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. Cellular oncology (Dordrecht). 2016 Review GET IT
Times cited: 17
Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016 Academic Article GET IT
Times cited: 140
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature medicine. 2016 Academic Article GET IT
Times cited: 246
Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers. EBioMedicine. 2016 Academic Article GET IT
Times cited: 64
Dehydroleucodine, a Sesquiterpene Lactone from Gynoxys verrucosa, Demonstrates Cytotoxic Activity against Human Leukemia Cells. Journal of natural products. 2016 Academic Article GET IT
Times cited: 17
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nature communications. 2016 Academic Article GET IT
Times cited: 24
In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche. Leukemia. 2015 Letter GET IT
Times cited: 41
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell reports. 2015 Academic Article GET IT
Times cited: 45
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. 2015 Academic Article GET IT
Times cited: 60
Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin. MedChemComm. 2015 Academic Article GET IT
Times cited: 322
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer cell. 2015 Academic Article GET IT
Times cited: 242
Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 85
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2015 Academic Article GET IT
Times cited: 70
CDK6 is a regulator of stem cells "Egr" to wake up. Blood. 2015 Comment GET IT
Times cited: 5
Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents. European journal of medicinal chemistry. 2014 Academic Article GET IT
Times cited: 18
Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. ACS chemical biology. 2014 Academic Article GET IT
Times cited: 20
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 45
Concise review: Leukemia stem cells in personalized medicine. Stem cells (Dayton, Ohio). 2014 Review GET IT
Times cited: 44
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. The Journal of clinical investigation. 2013 Academic Article GET IT
Times cited: 67
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leukemia research. 2013 Academic Article GET IT
Times cited: 18
Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia?. Current hematologic malignancy reports. 2013 Review GET IT
Times cited: 8
Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Experimental hematology. 2013 Academic Article GET IT
Times cited: 32
Iron and reactive oxygen species: friends or foes of cancer cells?. Antioxidants & redox signaling. 2013 Review GET IT
Times cited: 127
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer discovery. 2012 Academic Article GET IT
Times cited: 74
Acute myelogenous leukemia stem cells: from Bench to Bedside. Cancer letters. 2012 Review GET IT
Times cited: 39
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature chemical biology. 2011 Academic Article GET IT
Times cited: 213
Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy. Bioorganic & medicinal chemistry letters. 2011 Academic Article GET IT
Times cited: 19
Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture. Bioorganic & medicinal chemistry letters. 2011 Academic Article GET IT
Times cited: 8
Design, synthesis, and evaluation of small molecule Hsp90 probes. Bioorganic & medicinal chemistry. 2011 Review GET IT
Times cited: 39
Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 2010 Academic Article GET IT
Times cited: 69
The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British journal of haematology. 2010 Academic Article GET IT
Times cited: 59
Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. PloS one. 2009 Academic Article GET IT
Times cited: 56
Acute myeloid leukemia stem cells: seek and destroy. Expert review of hematology. 2009 Review GET IT
Times cited: 42
Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorganic & medicinal chemistry letters. 2009 Academic Article GET IT
Times cited: 158
Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia. 2009 Academic Article GET IT
Times cited: 20
Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology. Cancer cell. 2009 Comment GET IT
Times cited: 7
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 2008 Academic Article GET IT
Times cited: 161
The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008 Academic Article GET IT
Times cited: 140
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007 Academic Article GET IT
Times cited: 338
Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 2007 Academic Article GET IT
Times cited: 101
Cancer stem cells. The New England journal of medicine. 2006 Review GET IT
Times cited: 1356
Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone. 2006 Academic Article GET IT
Times cited: 83
Feverfew: weeding out the root of leukaemia. Expert opinion on biological therapy. 2005 Editorial Article GET IT
Times cited: 30
Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Molecular and cellular biology. 2005 Academic Article GET IT
Times cited: 79
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005 Academic Article GET IT
Times cited: 585
Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 2004 Review GET IT
Times cited: 114
Considerations for targeting malignant stem cells in leukemia. Cancer control : journal of the Moffitt Cancer Center. 2004 Review GET IT
Times cited: 69
Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Molecular and cellular biology. 2003 Academic Article GET IT
Times cited: 170
Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2002 Academic Article GET IT
Times cited: 393
Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001 Academic Article GET IT
Times cited: 673
Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 2001 Academic Article GET IT
Times cited: 46
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000 Academic Article GET IT
Times cited: 652
Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. Blood. 2000 Academic Article GET IT
Times cited: 136
Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system. British journal of pharmacology. 1986 Academic Article GET IT
Times cited: 62

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

3D co-culture system to characterize and target leukemia stem cells awarded by National Cancer Institute Principal Investigator 2020 - 2023

Mutational and Aging Risk Factors for Myelodysplastic Syndrome awarded by United States Department of Defense Co-Investigator 2023 - 2026
Pre-malignant mutation landscape and risk factors for progression to hematologic cancers awarded by National Cancer Institute Co-Investigator 2021 - 2026
Clonal Hematopoiesis as a determinant for bone marrow toxicities for targeted radiation therapies in prostate cancer. awarded by United States Department of Defense Co-Investigator 2022 - 2025
Clonal Hematopoeisis in HIV and Aging awarded by National Institute on Aging Co-Investigator 2020 - 2024
Janssen Biopharma Agreement awarded by Janssen Biotech Inc. Co-Investigator 2020 - 2023

Molecular Mechanisms of eIF4E mediated transformation awarded by National Cancer Institute Principal Investigator Subaward 2021 - 2026
Targeted Small Molecule Inhibitors for Inv(16) Leukemia awarded by National Cancer Institute Principal Investigator Subaward 2018 - 2023

more ...

less ...

Background

education and training

Ph.D., University of Kentucky 2002
B.S., University of Guanajuato (Mexico) 1997

Contact

full name

Monica L Guzman

primary email

mlg2007@med.cornell.edu

VIVO Weill Cornell Medical College

Monica L Guzman Associate Professor of Pharmacology in Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email